keynote-189 – KEYNOTE

 · Treatment

Jul 11, 2018 · KEYNOTE-189 was the logical follow-up of this trial. It was a randomized phase III trial with 2:1 randomization of platinum, either carboplatin or cisplatin, combined with pemetrexed plus or minus

Apr 16, 2018 · KEYNOTE-189 is a randomized, double-blind, phase III study in patients with metastatic nonsquamous NSCLC who received no prior treatment for metastatic disease. Patients (616) were randomized, 2:1, to receive pemetrexed and a platinum-based chemotherapy plus either pembrolizumab (test arm) or placebo (control arm).

Nov 08, 2019 · KEYNOTE-189 . The first presentation was by Leena Gandhi, MD, PhD, director of thoracic medical oncology at NYU Langone in New York City, and covered the KEYNOTE-189 trial comparing first-line

Jul 18, 2018 · Corey J. Langer, MD, FACP, discusses the design and outcomes of the KEYNOTE-189 study in nonsquamous metastatic NSCLC and considers its significance in sequencing therapy for appropriate patients.

[PDF]

KEYNOTE-189: Updated Overall Survival and Progression After the Next Line of Therapy With Pembrolizumab plus Chemotherapy With Pemetrexed and Platinum vs Placebo plus Chemotherapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer

Apr 17, 2018 · As reported at the American Association for Cancer Research (AACR) Meeting (Abstract CT075) in the The New England Journal of Medicine by Gandhi et al, the first interim analysis of the phase III KEYNOTE-189 trial has shown significant improvement in overall and progression-free survival with the addition of pembrolizumab (Keytruda) to chemotherapy in patients with metastatic

Jan 16, 2018 · BRIEF-Merck & Co Says Keytruda Phase 3 Keynote-189 Trial Met Its Dual Primary Endpoints. 1 Min Read. Jan 16 (Reuters) – Merck & Co Inc: * MERCK’S KEYTRUDA(R) (PEMBROLIZUMAB) SIGNIFICANTLY

[PDF]

KEYNOTE-189 trial is provided in the Supplementary Appendix, available at NEJM.org. This article was published on April 16, 2018, at NEJM.org. N Engl J Med 2018;378:2078-92. DOI: 10.1056/NEJMoa1801005

This is an efficacy and safety study of pembrolizumab (MK-3475) combined with pemetrexed/platinum chemotherapy versus pemetrexed/platinum chemotherapy alone in participants with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who have not previously received systemic therapy for advanced disease.

Jan 16, 2018 · KEYNOTE-189 is a randomized, double blind, placebo controlled, Phase 3 study (ClinicalTrials.gov, NCT02578680) investigating KEYTRUDA (pembrolizumab) in combination with pemetrexed and cisplatin

Roy Herbst, MD, PhD: KEYNOTE-189 is an important study because it took pembrolizumab, which we know can be used as a single agent in people who are PD-L1 [programmed death-ligand 1]

Jul 11, 2018 · Hossein Borghaei, DO, and Corey J. Langer, MD, share insight into the trial design and results of KEYNOTE-189, which combined chemotherapy with pembrolizumab as

Longest Follow-Up Data for KEYTRUDA in Lung Cancer to Date Showed Five-Year Overall Survival Rate of 23.2% with KEYTRUDA in Treatment-Naïve Patients and 15.5% in Previously Treated Patients with Advanced NSCLC in KEYNOTE-001 Trial Updated Overall Survival Analysis and New Data for Disease Progression After Next-Line Treatment (Progression-Free Survival 2) from KEYNOTE-189 Trial in

Nov 08, 2019 · I believe that on a different day, when not presented immediately after the results of KEYNOTE-189, the CheckMate-227 trial would be considered more

Sep 30, 2015 · In this study, participants with advanced or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or Siewert type I adenocarcinoma of the esophagogastric junction (EGJ) that had progressed after first-line standard therapy were randomized to receive either pembrolizumab (MK-3475) OR the Investigator’s choice of standard chemotherapy with paclitaxel, docetaxel, or irinotecan.

Home About cancer Find a clinical trial A trial looking at pembrolizumab and chemotherapy for non small cell lung cancer (KEYNOTE 189) A trial looking at pembrolizumab and chemotherapy for non small cell lung cancer (KEYNOTE 189) Please note – this trial is no longer recruiting patients.

 ·

May 26, 2019 · KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC.

Cited by: 4

6月16日、米メルク社は、進行非小細胞肺がんの初回治療に対する免疫チェックポイント阻害剤PD-1抗体ペムブロリズマブ(キートルーダ)の臨床試験(Keynote-024試験)結果を公表した。

Jan 16, 2018 · Combining pembrolizumab (Keytruda) with chemotherapy in the frontline setting improved survival in patients with nonsquamous non–small cell lung cancer (NSCLC), according to

Jan 16, 2018 · Merck’s Keytruda has done it again.The company reported data from its Phase III KEYNOTE-189 clinical trial of Keytruda in combination with pemetrexed (Alimta) and cisplatin or carboplatin in first-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC). It met both primary endpoints. The two primary endpoints were overall survival (OS) and progression-free

KEYNOTE-189 is a randomized, double-blind, phase III study in patients with metastatic nonsquamous NSCLC who received no prior treatment for metastatic disease. Patients (616) were randomized, 2:1, to receive pemetrexed and a platinum-based chemotherapy plus either pembrolizumab (test arm) or placebo (control arm).

 ·

May 31, 2018 · 1. N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

Cited by: 915

このサイトでは、医療用医薬品を適正にご使用いただくため、医師、歯科医師及び薬剤師などの 医療関係者の方を対象に、主としてmsd株式会社の医療用医薬品に関する情報を提供しています。

【keynote-189試験】進行非扁平上皮非小細胞肺癌1次治療. 今回の承認の根拠となる臨床試験が「keynote-189」です。 参考 nejm. keynote-189(フェーズⅢ)概要

Jan 17, 2018 · The phase III KEYNOTE-189 trial—investigating pembrolizumab (Keytruda) in combination with pemetrexed (Alimta) and cisplatin or carboplatin for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer (NSCLC)—met its dual primary endpoints of overall survival

Apr 27, 2018 · Dr. Jack West reviews the trial design, efficacy endpoints, and toxicity results of the KEYNOTE-189 trial of pembrolizumab or placebo added to

Sep 20, 2018 · KEYNOTE-189 explored the combination of that with chemotherapy. When you look at the KEYNOTE-189 data, and you divide the PD-L1 subsets into greater than 50%, 1% to 49%, and then less than 1%, we would call those negative. There was a

Apr 16, 2018 · Newly diagnosed lung cancer patients are half as likely to die if they take a Merck drug alongside standard chemotherapy, according to new trial data that eclipsed doctors’ expectations.

著者: Damian Garde

Sep 20, 2018 · Mark A. Socinski, MD: I think KEYNOTE-189 established the regimen of carboplatin-pemetrexed plus pembrolizumab as a standard. One of the issues we’re often faced with is, can you change up the chemotherapy part of it? Could you substitute, for instance, paclitaxel or say nab-paclitaxel, for the

 ·

KEYNOTE-189 was a phase III, randomized, multicenter, double-blind, active-controlled study investigating the safety and efficacy of ALIMTA + KEYTRUDA with platinum chemotherapy (cisplatin or carboplatin) (n=410) vs ALIMTA + placebo with platinum chemotherapy (n=206) in previously untreated patients with nonsquamous mNSCLC.

Dr Marina Garassino speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about the analysis of NSCLC patients with brain and liver metastases in the KEYNOTE 189 trial. Dr Garassino states the frequency of brain and liver metastases in this disease type, along with

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from KEYNOTE-189, a pivotal Phase 3 trial evaluating KEYTRUDA ® , Merck’s anti-PD-1 therapy, in combination with pemetrexed (ALIMTA®) and cisplatin or carboplatin for the first-line treatment of metastatic nonsquamous no

Abstract. Background: The premise that chemotherapy and immunotherapy may provide greater benefit than pembro or chemotherapy alone was supported by KEYNOTE-021 cohort G, in which pembro + pem + carboplatin significantly improved ORR and PFS over pem + carboplatin in patients (pts) with advanced nonsquamous NSCLC. We present results of the KEYNOTE-189 study of pembro + pem-platinum vs

AACR 2018: Frontline pembrolizumab plus chemotherapy in NSCLC reduces the risk of death by more than 50%. The Phase III KEYNOTE-189 trial combined pembrolizumab (Keytruda®) plus standard of care platinum-based chemotherapy in non-squamous non–small cell lung cancer (NSCLC) without EGFR or ALK mutations (NCT0278680).

[PDF]

KEYNOTE-189 . Randomized, Double-Blind, Phase 3 Study of Pembrolizumab or Placebo plus Pemetrexed and Platinum as First-Line Therapy for Metastatic NSCLC . KEYNOTE-054 . Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Efficacy and safety results from the double-blinded Phase 3 trial

Merck (MRK) PT Lowered to $67 at UBS on ‘Keynote-189 Delay As Feared’ Article Related following the announcement that management would push out results into early 2019 for Keynote-189 in

 ·

1. Lancet Oncol. 2016 Nov;17(11):1497-1508. doi: 10.1016/S1470-2045(16)30498-3. Epub 2016 Oct 10. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

keynote-189的研究结果正在改变临床实践。这个iii期研究结果显示:无论pd-l1表达如何,所有组患者的总反应率(orr),无进展生存期(pfs)和总生存期(os)都显著提高;同时将死亡风险减半,这是对于无egfr或alk突变的晚期非鳞nsclc患者前所未有的治疗效果。

keynote-189の結果が論文化されていたので読んでみた。 何分、初回の中間解析で有効中止となってしまったものだから、生存解析の結果はまだまだ未成熟と言わざるを得ない。

Apr 16, 2018 · Merck’s Keytruda-chemo combo is already approved in first-line lung cancer based on phase 2 data, but that FDA nod requires backup from a larger phase 3

Dec 18, 2017 · Keynote-189 study. In its 3Q17 earnings conference call, Merck & Co. announced its plans to capture long-term overall survival data in its pivotal Keynote-189

keynote-189では、egfr変異、alk転座が認められない未治療の進行非小細胞肺がん患者が対象だったので、ドライバー遺伝子変異のある人への効果は不明です。

With profound results, Keynote-189 has led to change in the vast majority of U.S.-based oncologists, so now it’s time to take a closer look. Dr. Shira Johnson welcomes Dr. Howard Jack West, who leads us on a deep dive into the clinical trial.

Jan 16, 2018 · Merck extends all-important lung-cancer lead with phase 3 Keytruda combo win. by Carly Helfand | Jan 16, 2018 11:38am. In Keynote-189, Merck’s Keytruda, in tandem with chemo, hit primary endpoints

[PDF]

KEYNOTE-189 study of platinum and pemetrexed with or without pembrolizumab in patients with non-squamous non–small-cell lung cancer (NCT02578680) and the KEYNOTE-407 study of carboplatin and paclitaxel or nab-paclitaxel with or without pembrolizumab

Dow’s Merck Plunges To 17-Month Low On Growing Keytruda Worries Licensing. It also delayed a Phase 3 study called Keynote-189 and added overall survival as a key goal for that trial.

 ·

Cookie Notice. This site uses tracking technologies through the use of permanent cookies and web beacons/pixel tags. By default, cookies are set to “Allow all cookies.”

KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC

 ·

Results of the ongoing double-blind, phase 3 KEYNOTE-189 study of carboplatin or cisplatin and pemetrexed with or without pembrolizumab for non-squamous NSCLC (ClinicalTrials.gov, number NCT02578680) might provide a better opportunity to assess the relationship between PD-L1 expression and efficacy of pembrolizumab plus chemotherapy in view

Jan 17, 2018 · Phase 3 Keynote-189 trial that investigated Keytruda (in combos with either cisplatin or carboplatin) for the 1st-line Rx of patients with metastatic non-small cell lung cancer (“NSCLC”) posted

KEYNOTE-189 is the confirmatory trial for KEYNOTE-021 (Cohort G), a Phase 2 study that made KEYTRUDA the only FDA-approved anti-PD-1 therapy in combination with chemotherapy (pemetrexed plus carboplatin) for the first-line treatment of patients with metastatic nonsquamous NSCLC, regardless of PD-L1 expression. If approved by the FDA

【方法】 この2重盲検、第3相試験で、未治療のEGFR陰性ALK陰性の転移性非扁平上皮非小細胞肺癌616例において、2:1の割合でプラチナ+ペメトレキセド+ペンブロリズマブ200mgあるいはプラセボを3週毎に4サイクル行い、その後、トータル35サイクルまでペメトレキセド維持療法に加えてペンブロリ

keynote-189試験(進行非小細胞非扁平上皮肺癌への初回治療として、シスプラチンもしくはカルボプラチン+ペメトレキセド併用療法にペンブロリズマブを上乗せすることの意義を検証する試験)において、いずれも主要評価項目として設定されていた全生存

By choosing to continue, you are confirming that you are a healthcare professional. VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature).

Keynote 189: Tumor mutational burden not significantly associated with efficacy of pembrolizumab. International Association for the Study of Lung Cancer. Meeting IASLC 2019 World Conference on

Jun 04, 2018 · The improvement was seen in patients with previously untreated advanced/metastatic NSCLC without EGFR or ALK mutations and PD-L1 TPS 1% or

 ·

Jun 01, 2018 · 9021. Background: In the double-blind, phase 3 KEYNOTE-189 study (NCT02578680), pembro + pem + plt significantly improved OS and PFS over pbo + pem + plt as first-line therapy for nonsquamous NSCLC. Grade 3-5 drug-related AE rates were higher with pembro. We report the prespecified patient-reported outcome (PRO) analyses from KEYNOTE-189.

 ·

Jan 16, 2018 · Merck & Co. Inc. shares MRK, +0.18% jumped almost 7% Tuesday, after the company announced positive results in a late-stage lung cancer trial.

Apr 30, 2018 · The FDA based the priority review designation on results from the phase 3 KEYNOTE-189 trial, which assessed pembrolizumab in combination with pemetrexed (Alimta, Eli Lilly) and chemotherapy